Article

The Prognostic Value of Whole-Blood PSMB5, CXCR4, POMP and RPL5 mRNA Expression in Patients with Multiple Myeloma Treated with Bortezomib

2021-01-25

Abstract excerpt

Proteasome inhibitors, like bortezomib, play a key role in the treatment of multiple myeloma (MM); however, most patients eventually relapse and eventually show multiple drug resistance, and the molecular mechanisms of this resistance remain unclear. The present study examines the expression of previously-described genes that may influence resistance to bortezomib treatment at the mRNA level (ABCB1, CXCR4, MAF, MA...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 70b9a374-072c-5ad6-ad5b-49ab439261ae
DOI: 10.20944/preprints202012.0287.v2

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

The Prognostic Value of Whole-Blood PSMB5, CXCR4, POMP and RPL5 mRNA Expression in Patients with Multiple Myeloma Treated with BortezomibDOI 10.20944/preprints202012.0287.v2Read

Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein.Semantic proximity Read

A gene expression signature distinguishes innate response and resistance to proteasome inhibitors in multiple myelomaSemantic proximity Read

RPL5 on 1p22.1 is recurrently deleted in multiple myeloma and its expression is linked to bortezomib response.Semantic proximity Read

PSMB7 Is a Key Gene Involved in the Development of Multiple Myeloma and Resistance to BortezomibSemantic proximity Read

Bortezomib-resistant myeloma cell lines: a role for mutated PSMB5 in preventing the accumulation of unfolded proteins and fatal ER stress.Semantic proximity Read

Overcoming bortezomib resistance in multiple myelomaSemantic proximity Read

Different Strategies to Overcome Resistance to Proteasome Inhibitors—A Summary 20 Years after Their IntroductionSemantic proximity Read

The proteasome: mechanisms of biology and markers of activity and response to treatment in multiple myelomaSemantic proximity Read

26S Proteasome Non-ATPase Regulatory Subunits 1 (PSMD1) and 3 (PSMD3) as Putative Targets for Cancer Prognosis and TherapySemantic proximity Read

Updates to the drug‐resistant mechanism of proteasome inhibitors in multiple myelomaSemantic proximity Read

Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomibSemantic proximity Read

Single-Nucleotide Variants and Epimutations Induce Proteasome Inhibitor Resistance in Multiple MyelomaSemantic proximity Read